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Alzheimer’s disease – lessons from pathology
Johannes Attems1* and Kurt A Jellinger2Abstract
Recent epidemiological and clinico-pathological data indicate considerable overlap between cerebrovascular
disease (CVD) and Alzheimer’s disease (AD) and suggest additive or synergistic effects of both pathologies on
cognitive decline. The most frequent vascular pathologies in the aging brain and in AD are cerebral amyloid
angiopathy and small vessel disease. Up to 84% of aged subjects show morphological substrates of CVD in addition
to AD pathology. AD brains with minor CVD, similar to pure vascular dementia, show subcortical vascular lesions in
about two-thirds, while in mixed type dementia (AD plus vascular dementia), multiple larger infarcts are more
frequent. Small infarcts in patients with full-blown AD have no impact on cognitive decline but are overwhelmed
by the severity of Alzheimer pathology, while in early stages of AD, cerebrovascular lesions may influence and
promote cognitive impairment, lowering the threshold for clinically overt dementia. Further studies are warranted
to elucidate the many hitherto unanswered questions regarding the overlap between CVD and AD as well as the
impact of both CVD and AD pathologies on the development and progression of dementia.
Keywords: Alzheimer’s disease, Cerebrovascular lesions, Cerebral amyloid angiopathy, Cognitive impairment,
Lacunes, Microinfarcts, Small vessel disease, White matter lesionsIntroduction
The interaction between cerebrovascular disease (CVD)
and Alzheimer’s disease (AD) is a topic of considerable
current interest. With age there is an increasing preva-
lence of coincident AD and CVD that is well recognized.
Since 50% to 84% of the brains of persons who die aged
80 to 90+ show appreciable cerebrovascular lesions
(CVL) [1], a specific problem is their impact in relation
to AD pathology [2-8]. CVD frequently occurs in brains
of both non-demented elderly and AD patients. The
burden of vascular and AD-type pathologies are leading
and independent causes of dementia in the elderly
[4,9-15], suggesting additive or synergistic effects of both
types of lesions on cognitive impairment [2,3,5,9,16-29].
Epidemiological studies have shown that AD and
CVD share common risk factors such as hypertension
during midlife, diabetes mellitus, smoking, apolipoprotein
E (ApoE) ε4 isoforms, hypercholesterolemia, homocystei-
nemia, and, in particular, age [16,30-34]. Cardiovascular* Correspondence: j.attems@ncl.ac.uk
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article, unless otherwise stated.risk factors, e.g., atrial fibrillation and congestive heart fail-
ure, have also been linked to the pathogenesis and progres-
sion of AD and are among the most important modifiable
risk factors for AD [35-42]. In the Medical Research
Council Cognitive Function and Ageing Study, vascular
risk factors were not associated with an increased burden
of AD pathology at death in old age, whereas cerebral
small vessel disease (SVD) and cardiovascular disease were
interrelated [43]. According to other studies, non-stroke
cardiovascular disease increases the risk of late-life de-
mentia but it is only a risk factor for AD in carriers of the
ApoEε4 allele, while the association between cardiovascu-
lar disease and dementia is not explained by genetic or
early life environmental factors common to both disorders
[44]. AD patients with concomitant CVD were reported
to be older and more severely demented, but have less se-
vere AD pathology than patients without CVD [23,45].
Review
Coincidence between cerebrovascular disease and
Alzheimer’s disease
There is a large body of literature regarding coincidence
or overlap of CVD and AD and its correlation withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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recently found to be stronger in cases with lower neuro-
fibrillary tangle pathology (i.e., lower neuritic Braak stages)
[5], similar to earlier studies on respective associations
with subcortical vascular pathology [6] and general CVD
[1]. However, others found an inverse relation between
neuritic Braak stage and cerebrovascular pathology in AD
[49]. A recent study assessed CVD in 5,715 autopsy cases
of the National Alzheimer’s Coordinating Center (NACC)
database, and confirmed previous data on the prevalence
of CVD in AD and the additive or interactive deleterious
effect of both AD and vascular pathologies on cognition
[6,9,47,50,51]. However, the role of combined cerebro-
vascular pathology and AD in dementia is still under
discussion and data obtained from epidemiological and
clinico-pathological studies regarding their relation are
controversial [13,17,22,23,52-55].
AD has been reported to present frequently together
with SVD, microvascular injury, and microscopic CVLs
[8,16,47,56-60]. SVD-induced ApoE leakage was associ-
ated with AD and accumulation of β-amyloid (Aβ) in
perivascular astrocytes [61] and transient induction of
Aβ deposition [62]. CVD has been shown to induce Aβ
deposition, which may by itself cause CVD, in particular
micro-vascular degeneration [63]. In addition, aging, per
se, has an effect on cerebral arteries in relation to AD
since such age related changes may impair the drainage
of soluble Aβ out of the brain, which in turn leads to Aβ
accumulation in vessel walls and brain parenchyma asso-
ciated with perturbation of cerebral perfusion and loss
of homeostasis of the neuronal environment due to en-
ergy failure [64,65]. It was also suggested that more Aβ
accumulates with age in brains of vascular dementia
(VaD) subjects compared to elderly without CVD [66].
Activity of smooth muscle actin (SMA) was reduced in
the brains of patients with late stage AD, while increased
arteriolar SMA expression together with frequent Aβ
plaques observed in the brains of non-demented subjects
suggests that increased SMA expression might represent
a physiological response to neurodegeneration that could
prevent or delay the onset of clinical dementia in sub-
jects with cerebral AD neuropathology [67]. Vascular
disease is thought by many authors to play a major role
in the pathogenesis of AD and some even consider AD
as being rather a primarily vascular than a neurode-
generative disorder [22,68-74]. Cerebral hypoperfusion-
inducing cortical microinfarcts may further aggravate
cognitive decline in AD [75]. However, AD pathology
alone more frequently accounts for dementia than both
macroscopic and microscopic infarcts [15] and, in late
stages of AD, concomitant SVLs do not significantly
influence the overall state and progression of cogni-
tive decline [45,54,76], the severity and extent of AD
pathology overwhelming the rather modest influenceof CVD on cognitive impairment [8,77,78]. These data
add further evidence for AD pathology (mainly neuro-
fibrillary tangles and neuritic plaques) being the main
morphological substrate of clinical dementia [51,79,80].
On the other hand, CVD has been associated with worse
cognitive performance in AD and neuropathological
studies report that CVD lowers the threshold for de-
mentia in subjects with a pathological diagnosis of
AD [5,6,8,9,13,17,23,51,53,81-83]. CVD has been sug-
gested to contribute to AD neuropathological changes
including selective brain atrophy and accumulation of
abnormal proteins such as Aβ [24,35,84,85]. Moreover,
AD pathology and subcortical vascular disease may in-
dependently affect cortical atrophy [86].
Vascular pathology in aging and Alzheimer’s disease
The types of vascular pathology in the aged human brain
include:
– Cerebral amyloid angiopathy (CAA);
– Cerebral atherosclerosis, SVD (in most cases caused
by hypertension, i.e., hypertensive vasculopathy), or
microvascular degeneration (tortuosity, fibro- and
lipohyalinosis,);
– Blood–brain barrier (BBB) dysfunction causing
white matter lesions (WMLs), microinfarctions,
lacunes or lacunar infarcts, and microbleeds [17,87].
All of these pathologies may disrupt the integrity of
cerebral vessels and alter brain perfusion leading to
neuronal injury and cognitive impairment
CAA results from focal to widespread deposition of Aβ
within leptomeningeal and intracortical arteries, arterioles,
capillaries, and, rarely, veins causing fibrinoid necrosis, in-
timal thickening, and microaneurysms. In addition, perica-
pillary Aβ refers to Aβ depositions in the glia limitans and
adjacent neuropil, whereas in capillary CAA Aβ deposi-
tions are present in the capillary wall [88]. Sporadic CAA
is present in 82% to 98% of AD patients, often associated
with ApoE2 and ApoE4 alleles [80], but is also frequently
observed in brains of elderly non-demented individuals
with an age-related prevalence between 10% and al-
most 100% [17,89]. The occipital lobe has been repor-
ted to be the site most frequently and severely affected by
CAA, followed by either frontal, temporal, or parietal
lobes [89,90]. CAA may cause lobar intracerebral hemor-
rhages (ICH) and microbleeds [91]; it is indeed considered
a risk factor for non-traumatic ICHs in the elderly and is
present in up to 20% of all cases with ICH [92]. However,
in a large autopsy cohort, the prevalence of ICH was simi-
lar in cases with and without CAA (around 5%) [93,94].
Of note, the majority of cases with CAA-related ICH had
hypertension, suggesting that hypertension is an import-
ant additional causal factor in CAA-related ICHs [95,96].
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associated with incident lobar ICHs [97]. CAA has been
suggested to cause cortical microinfarcts [98,99], while
others did not confirm such an association [100]. Moder-
ate to severe CAA is considered to be an independent risk
factor for cognitive impairment [101].
The clinical diagnosis of CAA is based on the assess-
ment of associated CVLs by magnetic resonance imaging
(MRI)/cranial computerized tomography (CCT) and cli-
nical data. Correlations of these criteria with post-mortem
neuropathological findings indicate that the diagnosis of
probable CAA-related hemorrhage can be made intra
vitam with high accuracy [102-105]. In addition to the
presence of superficial siderosis, cerebral microbleeds,
cortical microinfarcts, and hypointensities in MRI ima-
ges [106-109], the use of Pittsburgh Compound-B (PiB)-
positron emission tomography (PET) is useful in detecting
CAA intra vitam [110,111], and a significant decrease
of both Aβ-40 and Aβ-42 in cerebrospinal fluid (CSF)
may prove useful in the diagnosis of CAA [112,113],
while in AD, Aβ-42 but not Aβ-40 are significantly
decreased [114].
SVD affects small arteries and arterioles and refers to
pathological changes similar to atherosclerosis that are
termed small vessel arteriosclerosis/atherosclerosis, lipo-
or fibrohyalinosis, or hypertensive arteriopathy [115].
They are common in basal ganglia and in the white mat-
ter, while small brainstem arteries usually develop ar-
teriosclerosis only in end stages of SVD and cortical
vessels usually do not show signs of SVD [116]. In AD
neither Aβ load nor metabolic deficit are dependent on
the age of disease onset, but patients with late-onset AD
show a significantly higher amount of SVD that influ-
ences the association between metabolic deficit and clin-
ical symptoms [117]. SVD is a frequent cause of white
matter lesions (WMLs; leukoaraiosis) that are increasingly
detected by neuroimaging [118-121]. Enlarged perivas-
cular spaces in the centrum semiovale are MRI markers
indicative of CAA (in the overlying cortex), while those in
basal ganglia are usually associated with hypertensive
arteriopathy [103,104]. Deep cerebral microbleeds (CMB)
are mainly linked to subcortical SVD, while both subcor-
tical SVD and CAA interact to increase the risk of lobar
CMBs [122,123]. The associated morphological findings
include demyelination, axon loss, lacunar infarcts, or en-
larged perivascular spaces, most frequently in the frontal,
parietal, and occipital white matter [124]. Frontal lobe
WMLs have been shown to be associated with neurofibril-
lary pathology, particularly in the oldest old, while there
was no relationship with neocortical Aβ load [125]. Rou-
tine histological assessment may underrate mild to moder-
ate subcortical vascular lesions, but MRI imaging of fixed
post-mortem brains reliably reflects subcortical vascular
pathology of the white matter [126,127].BBB dysfunctions related to SVD leading to a leakage
of plasma proteins into enlarged perivascular spaces
[61,128] have been described in WMLs and lacunar stroke
[129,130]. These observations point towards SVD-related
alterations of the pre-capillary BBB segment which are in-
volved in the pathogenesis of WMLs/lacunar infarcts and
associated with vascular lesions in addition to AD-related
changes [61,116]. Thus, chronic plasma protein leakage
into the brain and retention of extracellular fluid due to
altered perivascular clearance may contribute to the de-
velopment of WMLs and/or lacunar infarcts [2,3,87].
Damage to the vasculature may, in turn, impair the BBB
integrity as one mechanism by which WMLs may evolve
[124]. Mechanisms leading to BBB leakage in aging brains
are complex, including oxidative damage and the activa-
tion of proteases, matrix metalloproteinases, and cycloox-
ygenases [131]. Evidence of early increase of BBB changes
and their progression with severity of AD-type pathology
suggest that BBB dysfunction contributes to damage in
the aging brain [132].
Atherosclerosis is a very common vessel disorder in
elderly individuals, frequently affecting large- to medium-
sized arteries of the entire cardiovascular system (large-
vessel disease; LVD). With respect to the cerebrum, it
mainly affects the circle of Willis and the carotid arteries,
in particular at the level of the carotic bifurcation. It
causes narrowing of the arteries’ lumina, thereby reducing
the blood blow for the supported region, while rupture of
atherosclerotic plaques often leads to thrombosis that re-
sults in either occlusion of the vessel or thromboembo-
lisms. Depending on the size of the embolus, it may cause
lesions that range from “silent” infarcts or microinfarcts
to large cerebral infarcts with overt clinical symptoms.
“Silent” lacunar infarcts are frequently detected by MRI or
CCT and are not accompanied by any overt clinical symp-
toms, but double the risk of subsequent stroke and de-
mentia [133]. They have been shown to be associated with
atrophy in multiple subcortical structures, ventricular en-
largement, and widespread cortical thinning, supporting
the assumption of a vascular contribution to neurodege-
neration and cognitive impairment [134]. As opposed to
large and lacunar infarcts, cortical microinfarcts (CMI)
are usually not visible at gross neuropathological examin-
ation. Due to the location of the underlying vessel dis-
order, multiple cortical CMIs are often associated with
CAA, whereas subcortical microinfarcts are mainly linked
to SVD or atherosclerosis-related embolism [135]. A sys-
temic review of CMIs reported frequencies of 43% in pa-
tients with AD and 24% in non-demented older adults
[136], while a 7-Tesla MRI study revealed CMI occur-
rence in 55% of early AD and 45% of non-demented
age-matched controls [137].
Widespread CAA and SVD have been suggested to
contribute to neurodegeneration in AD [116]. Moreover,
Table 1 Types and location of cerebrovascular lesions in
vascular dementia (total 188)
Multiple infarcts (61 = 32.5%)
MCA bilateral 4
MCA left/right 9
MCA bilat. + PCAS/PCAD 2/1
MCA bilat. + PCA bilat. 2
MCAS + PCAS 4
MCAD + PCAD 4
PCA bilateral 3
PCA left/right 5/7
ACAS + MCAS 2
ACAD 1
Multiple cortico-subcortico bilateral 12
Multiple cortico-subcortico left hem. 2
SAE (subcortical) (108 = 57.4%)
Basal ganglia 21
Basal ganglia + white matter 31
Basal ganglia + thalamus (+white matter) 33
Basal ganglia brainstem (+thalamus) 23
SID/strategic infarcts (19 = 10.1%)
Thalamus bilateral 9
Thalamus left 2
Thalamus + hippocampus 8
Abbreviations: ACAD, Anterior cerebral artery dexter; ACAS, Anterior cerebral
artery sinister; MCA, Middle cerebral artery; MCAD, Middle cerebral artery
dexter; MCAS, Middle cerebral artery sinister; PCA, Posterior cerebral artery;
PCAD, Posterior cerebral artery dexter; PCAS, Posterior cerebral artery sinister;
SAE, Subcortical arteriosclerotic encephalopathy; SID, strategic
infarct dementia.
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ally linked to AD [138-140], and the presence of large-
vessel CVD was strongly associated with an increased
frequency of neuritic plaques, suggesting a common eti-
ology or a reciprocal regulation for atherosclerosis and
AD [138,141]. Others, however, saw no direct associ-
ation between large-vessel cerebral atherosclerosis and
AD pathology [142], suggesting that atherosclerosis of
the intracranial vessels is an independent and important
risk factor for dementia due to potentially reversible
pathways unrelated to AD pathology and stroke [143].
The pathophysiology of VaD has been critically reviewed
recently [48,144-146].
Topographical distribution of cerebrovascular lesions
In AD brains with minor CVD the majority of CVLs are
lacunar infarcts in basal ganglia and white matter, and
multiple micro-infarcts. This pattern of topographical
distribution of CVLs is very similar to the one seen in
“pure” vascular dementia (VaD without AD pathology
beyond age-related lesions), where around 68% are lacu-
nar infarcts in subcortical brain areas or strategic in-
farcts involving the thalamus or hippocampus, whereas
only 32.5% were multiple large cortico-subcortical in-
farcts (Table 1). By contrast, mixed dementia (AD + severe
CVD), according to our experience, is more frequently
characterized by large or lobar infarcts, and multiple
cortico-subcortical lesions (56.6%) than small subcor-
tical lacunar infarcts, micro-infarcts, or strategic in-
farcts (43.4%, Table 2), suggesting different pathogenic
mechanisms between these types of disorders [2,3]. In
both pure VaD and AD+minor CVD, microangiopathy
(SVD) appears more important than in mixed dementia.
The type and average prevalence of CVLs in AD, VaD,
mixed dementia, and aged controls is shown in Table 3
[147]. The combination of two or more pathological pro-
cesses may influence the severity of cognitive deficits,
unmasking preclinical dementia due to mild AD lesions,
while small CVLs alone, seen in 10% to 50% of aged cog-
nitively unimpaired controls, are not likely to account for
a single cause of dementia.
Cerebrovascular and Alzheimer’s disease pathology in
demented and non-demented elderly
In a series of 300 autopsy cases of AD, Kalaria and
Ballard [148] reported 98% CAA, 100% microvascular
degeneration, 31% infarcts of all sizes, and 7% intracere-
bral hemorrhage, while Olichney [149], in a cohort of
248 autopsy cases of AD, revealed a total of 48% CVLs,
with 31% microinfarcts, 12.5% large infarcts, and 13.5%
hemorrhages. Comparing 173 autopsy-proven AD cases
and 130 age-matched controls, CVL were significantly
less frequent in controls (42.4%) as compared to AD
(56.4%, P <0.05), and CAA was seen in 97.2% of ADcases, out of which 26% showed severe degrees [150]. In
a population-based study of 419 demented persons, with
neuropathological data available in 89 (21%), the neuro-
pathological diagnoses were AD (51%), VaD (13%), com-
bined AD + VaD (12%), and others (24%). Criteria for
pure VaD using imaging results (Mayo Clinic criteria)
showed 75% sensitivity and 81% specificity [151]. In a
UK population-based autopsy study on elderly subjects
(n =209, 48% demented), neuropathological evidence of
CVD was found in 78% and of AD in 70%. The propor-
tion of multiple CVL was higher in the demented group,
while only 21% of clinically-demented patients showed
“pure” AD pathology at post-mortem, indicating that
most patients had mixed disease [152]. In a retrospective
series of 730 autopsy cases of AD and 535 age-matched
controls, using a four-grade scale for the severity of CVLs,
the total prevalence of CVD in AD was significantly
higher than in controls (31.6% vs. 23.4%) [153]. In a popu-
lation based longitudinal study of over-80-year-old brain
donors from Cambridge, UK, 53% of subjects presented
with clinical dementia. In those cases, neuropathological
Table 2 Types and location of cerebrovascular lesions in
mixed dementia (n = 83)
1) AD + Multiple infarcts (47 = 56.6%)
MCA bilateral 7
MCA left 6
MCA right (+ lacunes basal ganglia) 3/1
MCA + ACA bilat. 1
MCA + PCA left 2
MCA + PCA right 1
MCA + PCA left/right 3/3
MCA bilat. +PCAD 1
PCA bilateral 2
Multiple cort. and subcort. bilateral 13
Multiple left hemisphere 4
2) AD + SAE (subcortical) (33 = 39.8%)
Lacunes basal ganglia 15
Lacunes basal ganglia + white matter 8
Lacunes basal ganglia + thalamus 10
3) AD + SID/strategic infarcts (3 = 3.6%)
Thalamus bilateral 2
Thalamus + hippocampus 1
Abbreviations: ACA, Anterior cerebral artery; AD, Alzheimer’s disease; MCA,
Middle cerebral artery; PCA, Posterior cerebral artery; SAE, Subcortical
arteriosclerotic encephalopathy; SID, strategic infarct dementia.
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VaD in 4%, while 22% showed mixed pathologies and 1%
dementia with Lewy bodies. AD and CVD frequently co-
existed in the very old [154]. Among 190 older autopsy
cases, 68% had CVLs, vascular score was associated with
dementia (OR, 1.6), AD (OR, 1.5), and VaD (OR, 2.0).
Leukoencephalopathy, large infarcts, and higher vascular
burden were associated with clinical dementia [18]. Ana-
lysis of 4,629 cases of the NACC database with autopsy-
confirmed neurodegenerative AD classified 79.7% as
having CVD [37].Table 3 Common lesions in AD, VaD, MIX, and aged controls
Pathological feature AD [%] V
Cerebral amyloid angiopathy 98 30
Small vessel disease/MVD ~50 >
Total infarctions 10–20 10
Microinfarcts/lacunes 30–46 70
Intracerebral hemorrhage 10–15 15
White matter pathology 40 80
Loss of cholinergic markers 75 40
CVD/atherosclerosis 45–60 60
Abbreviations: AD, Alzheimer’s disease; CVD, Cerebrovascular disease; MIX, mixed ty
VaD, Vascular dementia.In a recent study from the Oxford Project to Investi-
gate Memory and Ageing, assessment of the severity of
SVD in 161 cases of autopsy-confirmed AD gave no re-
lationship between the SVD score and cognitive scores
acquired in the last two years of life nor to blood pres-
sure at entry; further, SVD scores were significantly lower
when compared with a cohort of cases with only CVD [8].
Assessment of 175 autopsy cases in the Baltimore Longi-
tudinal Study of Aging cohort found no relationship be-
tween the degree of atherosclerosis in the aorta, heart, and
intracranial vessels and the degree of AD pathology, while
the presence of intracranial atherosclerosis significantly
increased the odds of dementia, independent of cerebral
infarction [143].
A recent study from the NACC selected 835 subjects
that represent the AD continuum. While the cause of
mild to moderate dementia remained uncertain in 14%
of the patients, plaques and tangles independently pre-
dicted cognitive dysfunction, as did severe SVD, CAA,
and hippocampal sclerosis. Thus, concomitant CVD
strongly correlated with cognitive impairment in this sam-
ple selected to represent the AD pathology continuum,
confirming the uncertainty of AD clinico-pathological cor-
relations based only on neurofibrillary tangles and Aβ-
plaques [155]. Assessment of 856 participants of two
longitudinal clinico-pathological studies (Rush Memory
and Aging Project and Religious Orders Study, autopsy
rate 80%, mean age at death 88.2 ± 6.5 years) showed that
global AD pathology, Aβ-plaques, neurofibrillary tangles,
macroscopic infarcts, and neocortical Lewy bodies were
associated with faster rates of decline and explained
22%, 6%, 34%, 2%, and 8% of the variation in decline,
respectively. However, much of the variation in cogni-
tive decline remains unexplained, suggesting that other
important determinants of cognitive decline remain to
be identified [156].
In a consecutive autopsy series of 494 cases (257
autopsy-proven AD, mean age 83.1 ± 8.4 years and 237
age-matched non-demented controls), 42.7% of the AD(from [130])
aD [%] MIX [%] Aged controls [%]
~90 23–45
50 >50 ~20
0 30–40 >10
60–70 17–21
10 1–2
70–80 <20
~70
~60 30–53
pe dementia (AD plus vascular dementia); MVD, Microvascular disease;
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essential vascular pathology except for minor to moder-
ate CAA (50%) and without CVLs, compared to 66.8%
in age-matched controls, all showing low Braak stages
(P <0.01). Prevalence of CAA in AD was 94.1% (45% se-
vere degrees) as compared to 33.3% in controls. The se-
verity of CAA was significantly higher in AD brains with
CVLs compared to controls with similar vascular lesions
[157]. Minor and moderate vascular pathology in AD
were about twice as frequent as in controls (26.2% vs.
12.2% and 20.9% vs. 11.3%; P <0.01). On the other hand,
severe vascular pathology did not significantly differ be-
tween both groups (10.2% vs. 12.2%). Retrospective exa-
mination of the prevalence of CVD in a consecutive
autopsy series of 621 autopsy-proven AD cases and 486
age-matched controls, using a four-degree scale for cere-
brovascular pathology, showed a generally higher preva-
lence of CVLs in AD (67.8%) than in controls (29.4%);
severe CVLs (old/recent infarcts and hemorrhages) were
more frequent in AD (23.6%) than in controls (5.4%).
Likewise, the prevalence of cortico-subcortical infarcts
and subcortical vascular lesions was higher in AD
(41.2%) compared to controls (11.6%) [157]. Both the in-
cidence and severity of CVLs increased with higher
neuritic Braak stages as was reported in a previous study
[12]. In elderly subjects with and without dementia, the
prevalence of “pure” VaD (without other cerebral path-
ologies) ranged from 5% to 78% and in the oldest old
group from 4.5% to 46.8% [47], while the majority (24%
to 93%) showed mixed pathologies [158,159]. In the age
group 70 to 90+, the prevalence of VaD increased from
13% to 44.8%, compared to AD (23.6% to 57%) and
mixed dementia (2% to 86%) [47]. In contrast to AD and
mixed dementia, the prevalence of pure VaD decreased
after 80 years of age [145,158].
Cerebrovascular lesions are found in the majority of late-
onset AD and only in half of early-onset AD cases [160].
There are considerable differences in the pathological bur-
den in relation to age of onset of dementia, suggesting that
late onset is associated with increased vascular pathology
and lower AD burden [161,162]. However, in a 90+ study,
there was extensive overlap in pathology among those with
and without dementia; 22% of demented subjects did not
have significant pathology to account for their cognitive
impairment [163]. A specific caveat in this respect is
the effect of sample selection in incident-bases dementia
autopsy series [164]. Community samples tend to show
greater degrees of cerebrovascular pathology as compared
to hospital based samples; and the prevalence of mixed
AD/CVD was higher in the community-based RUSH
Memory and Aging Project (44%) than in the RUSH
Religious Order Study (28%). Therefore, the type of study
sample may strongly bias results and should be mentioned
as a possible contribution to variability of findings.Many studies emphasized multiple confounding path-
ologies in non-demented elderly subjects, in particular
CVLs, e.g., small or large cerebral infarcts, lacunes, and
WMLs, in up to 10% [10,165-167]. Among 418 non-
demented participants of the Religious Order Study (mean
age 88.5 ± 5.3 years), 35% showed macroscopic brain in-
farcts and 14.8% arteriosclerosis, while only 37.5% were
free of any CVD [168]. Various degrees of CAA have been
found in up to 75% of cognitively normal seniors [167].
Among 100 non-demented elderly, mild, moderate, and
severe intracranial atherosclerosis was present in 31%,
17%, and 6% of subjects, respectively. A lacunar state in
basal ganglia and/or white matter was observed in 73%,
hippocampal sclerosis in 3%, and mixed cerebral patholo-
gies in 6%, whereas only 9% were free of CVLs [169]. A re-
cent cross-sectional study in a community-based sample
of 72 cognitively normal older individuals (mean age
74.9 ± 5.7 years) confirmed that a substantial number
harbor neurodegeneration without Aβ burden, but as-
sociation of neurodegenerative lesions with CVD can
emerge through non-Aβ pathways within regions most
affected by AD [170].
Pathogenic factors
Microvascular changes in the aged brain and in AD
induce impairment of cerebral perfusion, in particular
decrease of regional blood flow, reduction of glucose
transport and utilization, loss of vascular innervation
with special impact on the cholinergic and transmitter
deficits in AD [171], impairment of neurovascular regula-
tion, ultrastructural changes in capillaries and basement
membranes due to deposition of Aβ, with breakdown of
the BBB and impairment of amyloid clearance. The patho-
genic chain of these and other deleterious effects, in a
vicious circle, finally produces either structural cerebral
disintegration (lacunes, infarcts, WMLs) with compro-
mised neuronal metabolism, mitochondrial deficiency,
oxidative stress, protein degradation, failure promoting
cytoskeletal lesions with deposition of Aβ, and formation
of neuritic lesions (e.g., neurofibrillary tangles). These fac-
tors induce brain atrophy with cognitive and memory
impairment (Figure 1) [147], although the complex cas-
cade of these and other noxious factors needs further
elucidation.
The role of vascular pathology as a factor contributing
to AD is a topic of current interest, with a wide overlap
between both disorders. Both hypertension and CAA are
associated with an increased prevalence of CVLs [157],
and both human and experimental studies in transgenic
mice overexpressing amyloid precursor protein sug-
gest that cerebrovascular effects of Aβ render the aged
brain more vulnerable to ischemic injury [172]. Both
atherosclerosis and CAA cause changes in microvas-
culature auto-regulation and thus may lead to myelin
Figure 1 Pathogenic factors for the development of mixed dementia. Modified from [147].
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gesting shared risk factors for all pathological changes
seen in AD and CVD. WMLs may be caused by both
CVD (hypoperfusion) and AD (retrograde degeneration),
they progress with age, and they are a considerable risk
factor for cognitive impairment [120,173,174]. They im-
pair frontal functions regardless of their location [175,176]
and increase the risk of dementia, particularly in pa-
tients with lacunar infarcts [177,178], causing functional
network disruption in cognitively-impaired individuals
compared with age-matched healthy elderly controls
[179,180]. Although WMLs and lacunes may be indepen-
dently associated with cognitive dysfunction [181,182],
WMLs in AD are significantly correlated to cortical and
medial temporal lobe atrophy [181-183], and, thus, are as-
sumed to contribute to cognitive decline [184]. Together
with cortical microinfarcts, WMLs may contribute to the
progression of cognitive impairment, but do not necessar-
ily interact with AD pathology to increase the likelihood
of dementia beyond their additive effect [20]. Further, the
neuropathological evaluation of focal and white matter
gliosis may have no clinical validity [185].
Conclusions
CVD has been suggested to be an important cause of
cognitive impairment in the elderly, both by itself or as a
catalyst for the conversion of low-grade AD to overt de-
mentia [186]. Hence, the combination of both AD and
vascular or other pathological processes, as seen in many
elderly persons, may coexist in the earlier stages of cog-
nitive decline and may influence its progression and se-
verity, thus representing a major diagnostic challenge notonly for clinicians but also for neuropathologists. Despite
multiple attempts, there is still a lack of consensus re-
garding the optimal means of incorporating vascular
disease into clinical and neuropathological classification
schemes for dementias. Therefore, an integrating rather
than a strictly taxonomic approach (instead of discrimin-
ating AD, VaD, and other diseases) to elucidate specific
pathophysiological mechanisms that contribute to de-
mentia phenotypes and neuropathological causes has been
proposed [37].
To improve the diagnostic specificity on the interac-
tion between AD and CVD pathologies, a multivariable
and multimodality algorithm is required. While struc-
tural MRI results have limited security and specificity, a
number of in vivo studies using functional MRI [187]
and amyloid and tau PET (e.g., PiB, florbetabin, fluteme-
tamole, etc.) [188-190] will enable the identification of
AD and CVD patients in clinical and research settings.
However, recent evidence comparing PiB-PET with post-
mortem or biopsy results raised doubts about this me-
thod as representative of Aβ loads in the living brain
[191,192] and PiB-positivity was observed in 55% of
non-demented subjects over 80 [193]. The recent de-
velopment of in vivo amyloid imaging enables further
pathological breakdown of SVD into pure forms and
mixed dementia based on the absence or presence of
amyloid pathology in the brain [194]. Modern CSF bio-
markers may support a direct relationship between SVD
and AD pathology [195], although in the Alzheimer Dis-
ease Neuroimaging Initiative that is focused on AD, no
interactions were noted between vascular risk factors and
AD biomarkers [26]. Therefore, differentiation of mixed
Attems and Jellinger BMC Medicine 2014, 12:206 Page 8 of 12
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ging evidence from autopsy, amyloid PET, functional MRI,
and CSF biomarker studies indicate that AD and CVD
exert additive rather than interactive adverse effects on
cognitive health, but interaction between various vascular
factors and amyloidosis/tauopathy still remain unresolved.
Further studies to more accurately elucidate the impact of
vascular disease and AD-related brain pathology are an
important challenge for neuroscience as such studies
could serve as a basis for the development of efficient the-
rapies against age associated dementias.
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